Covered recipient · General Payments record
AUGUST A FEOLA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$3,635.46
- Reported across 137 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $416.86 | 14 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Neurocrine BioSciences, Inc. | $101.85 | 1 |
| Novo Nordisk AS | $101.42 | 4 |
| Esperion Therapeutics, Inc. | $48.43 | 2 |
| Lilly USA, LLC | $47.56 | 2 |
| Acerta Pharma LLC | $30.61 | 1 |
| Exact Sciences Corporation | $24.41 | 1 |
| Amgen Inc. | $24.23 | 1 |
| GlaxoSmithKline, LLC. | $23.92 | 1 |
| ABBVIE INC. | $14.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.43 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103720916 | CMS |
| Amgen Inc. | $24.23 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117250109 | CMS |
| AstraZeneca Pharmaceuticals LP | $30.61 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105699166 | CMS |
| Esperion Therapeutics, Inc. | $22.94 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129434714 | CMS |
| Esperion Therapeutics, Inc. | $25.49 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129434716 | CMS |
| Exact Sciences Corporation | $24.41 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114655519 | CMS |
| GlaxoSmithKline, LLC. | $23.92 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116311403 | CMS |
| Lilly USA, LLC | $22.11 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136057998 | CMS |
| Lilly USA, LLC | $25.45 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136059080 | CMS |
| Neurocrine Biosciences, Inc. | $101.85 | 02/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150811995 | CMS |
| Novo Nordisk Inc | $23.12 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097058118 | CMS |
| Novo Nordisk Inc | $23.29 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097323144 | CMS |
| Novo Nordisk Inc | $31.87 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096857508 | CMS |
| Novo Nordisk Inc | $23.14 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097636403 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.